Aurobindo Pharmaceuticals or AUROPHARMA

It was founded in 1986 by Mr. P. V. Ramaprasad Reddy and Mr. K. Nityananda Reddy. Soon it also started its operation with a single unit manufacturing semisynthetic penicillin (SSPs) at Pondicherry, India. It has a possible product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardiovascular, gastroenterology, etc. The company is the market leader in semisynthetic penicillin drugs. It has overseas branches or the representative offices which are located in Ethiopia, Tanzania, Kenya, Uganda, Italy, Ghana, Vietnam, and the UK. It has also identified its international operations, which are catering to over 100 countries, as a significant engine of growth and expanding global network of marketing as well as manufacturing processes spread across countries like China, Japan, Brazil, Netherlands, Thailand, South Africa, UK, USA, Netherlands, Russia and many others which will further expand their international reach. Also, the subsidiaries in strategic pharmaceutical markets have positioned themselves to ride the challenges, which is powered by the strengths, and the brilliance and hard work of its global workforce, stellar track record, ever-growing infrastructure, and cost–competitiveness.

It provides various features and facilities which are listed below:

The fully integrated pharma company, Aurobindo Pharma is among the top 2 companies in India in terms of the consolidated revenues. It exports its products in over 150 countries across the world, with more than 90% of its revenues being derived from international operations.
Robust Product Portfolio By leveraging India’s globally competitive cost base with the talented team of scientists, the company has successfully launched a range of many affordable products that can be easily accessible across the globe. From the stage of discovery to the scene of development to commercialization, their growth is aided by cost-effective drug development as well as substantial manufacturing.

The Aurobindo Corporation has also invested significant resources in building a complete mega infrastructure for APIs and formulations with the purpose to emerge as a vertically integrated pharmaceutical company. USFDA approves its manufacturing units, UKMHRA, WHO, MCC–SA and ANVISA–Brazil In 2012 Aurobindo Pharma commenced a business journey into the peptides segment. It launched its operations in the Kingdom of Bahrain through a grand event which was held at Hotel Radisson Blu on Monday, 17th September 2012. And in April 2014, it also announced the completion of the previously announced acquisition which consisted of certain commercial operations in the areas of Western Europe from Actavis plc. Soon the agreement to acquire the Actavis operations was published in January 2014.

Some of the Products are described below:

Formulation–

In this segment, it manufactures formulation for the cardiovascular, central nervous system, gastroenterological, and anti-infectives. It has developed various formulations, which are namely Trandolapril, Captopril, Benazepril Hydrochloride, and so much more.

Active Pharmaceutical Ingredients (API) –

It has approximately five units for the APIs and the four other units for formulations that are designed for the regulated markets.

Organic Intermediates–

It manufactures a wide range of organic intermediates, namely Desmethyl Azithromycin, Methenamine, Benzimidazole, ECPPA, and many more.

Some of the Awards are below:

In 2011 Aurobindo Pharma received a Platinum Certificate of Outstanding Exports Award from Pharmexcil.

AUROPHARMA Share Price Chart